Transgene Awarded EUR 1.3 M Grant for Hepatitis C Therapeutic Vaccine Programme
Transgene S.A. announced that it has been awarded funding by the Lyon Biopole Competitiveness Cluster (Pole de competitivite) for the development of its therapeutic vaccine candidate against hepatitis C chronic infection (HCV). This funding is expected to total EUR 1.3 million over the next three years and will cover 30% of the research and development costs for this programme.
The grant aims at strengthening the development of Transgene's vaccine candidate TG4040 (MVA-HCV). TG4040 is currently undergoing preclinical studies and should enter Phase I/II trial by mid-2006 to treat patients not responding to standard therapy. The TG4040 development programme is carried out by Transgene's infectious diseases research team based in Lyon, France. Research units of INSERM, CNRS, Grenoble University Hospital and Lyon Civil Hospitals will also participate in the subsidised programme.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.